CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue
Tissue sales	$ 7,710,256	$ 8,643,299	$ 24,430,158	$ 24,427,853
Royalties and other	219,727	236,466	385,480	430,185
Total Revenue	7,929,983	8,879,765	24,815,638	24,858,038
Cost of tissue and medical devices sales	3,318,327	2,600,452	10,011,687	6,788,606
Gross Profit	4,611,656	6,279,313	14,803,951	18,069,432
Operating Expenses
General and administrative	2,764,328	2,439,229	7,877,697	7,349,852
Sales and marketing	4,053,679	3,352,394	12,057,389	11,333,946
Depreciation and amortization	97,923	88,112	304,771	302,392
Non-cash consulting expense	43,153	186,867	11,924	491,051
Total Operating Expenses	6,959,083	6,066,602	20,251,781	19,477,241
(Loss) Income from Operations	(2,347,427)	212,711	(5,447,830)	(1,407,809)
Other Income (Expense)
Interest expense	(1,197,370)	(867,894)	(3,436,006)	(1,276,946)
Change in warrant derivative liability	(849,288)	(125,972)	246,337	1,393,155
Other income (expense)	17,551	(1,738,202)	108,616	(1,544,035)
Total Other Expense	(2,029,107)	(2,732,068)	(3,081,053)	(1,427,826)
Net Loss Before (Provision) Benefit for Income Taxes	(4,376,534)	(2,519,357)	(8,528,883)	(2,835,635)
(Provision) Benefit for Income Taxes
Current	0	0	0	0
Deferred	0	0	0	0
Net Loss	$ (4,376,534)	$ (2,519,357)	$ (8,528,883)	$ (2,835,635)
Net loss per share:
Basic (in dollars per share)	$ (0.08)	$ (0.06)	$ (0.18)	$ (0.07)
Dilutive (in dollars per share)	$ (0.08)	$ (0.06)	$ (0.18)	$ (0.07)
Shares used in the computation:
Basic (in shares)	51,616,319	42,796,244	46,611,358	42,341,796
Dilutive (in shares)	51,616,319	42,796,244	46,611,358	42,341,796